Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis”

Article information

Clin Mol Hepatol. 2023;29(1):168-168

Publication date (electronic) : 2022 October 31

doi : https://doi.org/10.3350/cmh.2022.0328

Rujittika Mungmunpuntipantip^,1, Viroj Wiwanitkit²

¹Private Academic Consultant, Bangkok, Thailand

²Department of Research Center, Chandigarh University, Punjab, India

Corresponding author : Rujittika Mungmunpuntipantip Private Academic Consultant, 111 Bangkok 122, Bangkok 103300, Thailand Tel: +66-22564133662, Fax: +66-22564133662, E-mail: rujittika@gmail.com

Editor: Seung Up Kim, Yonsei University College of Medicine, Korea

Received 2022 October 21; Revised 2022 October 26; Accepted 2022 October 26.

Dear Editor,

We would like to share ideas on “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis.” [1] In contrast to liver transplant recipients, patients with chronic liver disease exhibited a good humoral response to the coronavirus disease 2019 (COVID-19) vaccination, according to Cheung et al. [1]. We also agree that COVID-19 is helpful in immunogenicity. The immunological response of a vaccine recipient with an underlying medical condition may be different from that of a healthy individual. Potential confounding factors must be taken into consideration while interpreting the current report. Prior asymptomatic COVID-19 infection is a possibility, and is not unusual [2]. If there is no method to rule out prior cases of asymptomatic COVID-19, it would be challenging to evaluate the effectiveness of the vaccine.